Key result
Female sex was associated with lower utilization of lipid-modifying agents (56.37% vs 65.44%; P<0.0001) and ACE-inhibitors (55.52% vs 59.99%; P<0.01) in patients with acute coronary syndromes.
Why the study?
Does female sex influence the utilization of evidence-based therapies in patients with acute coronary syndromes?
Population
6,558 patients with a final diagnosis of acute coronary syndromes from the Canadian Registry of ACS I and II
Comparison
Female sex vs Male sex
Design
Cohort
Authors
Loading...
May signal undertreatment of women with ACS; leaves open whether interventions can close gaps in evidence-based therapy use.
Observational (n=6,558)
Yes
Does female sex influence the utilization of evidence-based therapies in patients with acute coronary syndromes?
Absolute Event Rate: 56.37% vs 65.44%
p-value: p=<0.0001
Women with acute coronary syndromes are significantly less likely to receive evidence-based therapies compared to men, a disparity driven by age, heart failure, and lower rates of catheterization, though female sex remains an independent predictor of underutilization.
Bugiardini et al. (2011) conducted an observational in Acute coronary syndromes (n=6,558). Female sex vs. Male sex was evaluated on Receipt of lipid-modifying agents (p=<0.0001). Female sex was associated with lower utilization of lipid-modifying agents (56.37% vs 65.44%; P<0.0001) and ACE-inhibitors (55.52% vs 59.99%; P<0.01) in patients with acute coronary syndromes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: